Search

Search Constraints

You searched for: Author/Creator Bolstad, N

Search Results

1. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. (3rd September 2018)

3. OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study. (21st January 2022)

5. P483 Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial. (16th January 2018)

6. P696 Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial. (21st January 2022)

10. THU0700 Immunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study. (15th June 2017)